scholarly journals Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor-1 in colon cancer liver metastases

2009 ◽  
Vol 124 (8) ◽  
pp. 1860-1870 ◽  
Author(s):  
Martin Illemann ◽  
Nigel Bird ◽  
Ali Majeed ◽  
Ole D. Laerum ◽  
Leif R. Lund ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Liver Metastases ◽  
Plasminogen Activator ◽  
Expression Patterns ◽  
Plasminogen Activator Inhibitor ◽  
Urokinase Receptor ◽  
Plasminogen Activator Inhibitor 1 ◽  
Colon Cancer Liver Metastases ◽  
Activator Inhibitor

scholarly journals Leading-Edge Myofibroblasts in Human Colon Cancer Express Plasminogen Activator Inhibitor-1

2004 ◽  
Vol 122 (2) ◽  
pp. 256-265 ◽  
Author(s):  
Martin Illemann ◽  
Ulla Hansen ◽  
Hans Jørgen Nielsen ◽  
Peter A. Andreasen ◽  
Gunilla Høyer-Hansen ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Plasminogen Activator ◽  
Leading Edge ◽  
Plasminogen Activator Inhibitor ◽  
Human Colon ◽  
Plasminogen Activator Inhibitor 1 ◽  
Human Colon Cancer ◽  
Activator Inhibitor

943: Plasminogen Activator Inhibitor 1 (PAI-1) is Increased in Human Peyronie's Disease

2005 ◽  
Vol 173 (4S) ◽  
pp. 255-255 ◽  
Author(s):  
Hugo H. Davila ◽  
Thomas R. Magee ◽  
Freddy Zuniga ◽  
Jacob Rajfer ◽  
Nestor F. GonzalezCadavid
Keyword(s):  
Plasminogen Activator ◽  
Plasminogen Activator Inhibitor ◽  
Peyronie’S Disease ◽  
Plasminogen Activator Inhibitor 1 ◽  
Peyronie's Disease ◽  
Activator Inhibitor ◽  
Pai 1

Relationship of Plasminogen Activator Inhibitor-1 Levels following Thrombolytic Therapy with rt-PA as Compared to Streptokinase and Patency of Infarct Related Coronary Artery

1999 ◽  
Vol 82 (07) ◽  
pp. 104-108 ◽  
Author(s):  
Franck Paganelli ◽  
Marie Christine Alessi ◽  
Pierre Morange ◽  
Jean Michel Maixent ◽  
Samuel Lévy ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Thrombolytic Therapy ◽  
Plasminogen Activator ◽  
Plasminogen Activator Inhibitor ◽  
Control Group ◽  
Plasminogen Activator Inhibitor 1 ◽  
Vessel Patency ◽  
Activator Inhibitor ◽  
Pai 1

Summary Background: Type 1 plasminogen activator inhibitor (PAI-1) is considered to be risk factor for acute myocardial infarction (AMI). A rebound of circulating PAI-1 has been reported after rt-PA administration. We investigated the relationships between PAI-1 levels before and after thrombolytic therapy with streptokinase (SK) as compared to rt-PA and the patency of infarct-related arteries. Methods and Results: Fifty five consecutive patients with acute MI were randomized to strep-tokinase or rt-PA. The plasma PAI-1 levels were studied before and serially within 24 h after thrombolytic administration. Vessel patency was assessed by an angiogram at 5 ± 1days. The PAI-1 levels increased significantly with both rt-PA and SK as shown by the levels obtained from a control group of 10 patients treated with coronary angioplasty alone. However, the area under the PAI-1 curve was significantly higher with SK than with rt-PA (p <0.01) and the plasma PAI-1 levels peaked later with SK than with rt-PA (18 h versus 3 h respectively). Conversely to PAI-1 levels on admission, the PAI-1 levels after thrombolysis were related to vessel patency. Plasma PAI-1 levels 6 and 18 h after SK therapy and the area under the PAI-1 curve were significantly higher in patients with occluded arteries (p <0.002, p <0.04 and p <0.05 respectively).The same tendency was observed in the t-PA group without reaching significance. Conclusions: This study showed that the PAI-1 level increase is more pronounced after SK treatment than after t-PA treatment. There is a relationship between increased PAI-1 levels after thrombolytic therapy and poor patency. Therapeutic approaches aimed at quenching PAI-1 activity after thrombolysis might be of interest to improve the efficacy of thrombolytic therapy for acute myocardial infarction.

Sign in / Sign up

Export Citation Format

Share Document